Weiss Ratings restated their sell (d-) rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Wednesday,Weiss Ratings reports.
A number of other research firms have also weighed in on AKBA. Zacks Research lowered shares of Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.75.
Read Our Latest Stock Report on AKBA
Akebia Therapeutics Trading Down 4.8%
Institutional Trading of Akebia Therapeutics
Institutional investors have recently made changes to their positions in the company. Unified Investment Management raised its position in shares of Akebia Therapeutics by 47.8% during the 1st quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 5,500 shares during the period. E Fund Management Co. Ltd. raised its position in shares of Akebia Therapeutics by 51.9% during the 1st quarter. E Fund Management Co. Ltd. now owns 19,311 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 6,595 shares during the period. Abel Hall LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at approximately $39,000. Baird Financial Group Inc. raised its position in shares of Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at approximately $59,000. Hedge funds and other institutional investors own 33.92% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Read More
- Five stocks we like better than Akebia Therapeutics
- Insider Buying Explained: What Investors Need to Know
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- Canadian Penny Stocks: Can They Make You Rich?
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.